BEN-8744

About BenevolentAI

BenevolentAI's mission is to transform drug discovery by applying advanced artificial intelligence and machine learning to vast biomedical datasets. Its key achievement is the development of a proprietary, decade-invested knowledge graph and AI platform that generates novel, testable hypotheses for target identification and patient stratification. The company's strategy is dual-pronged: advancing an internal pipeline of drug candidates while securing strategic collaborations with large pharma to validate its platform and generate revenue. It became a publicly traded company on Euronext Amsterdam in 2022.

Therapeutic Areas

Other Ulcerative Colitis Drugs